References

• 1. Biggs R, Douglas AS, Macfarlane RC, Dacie JV, Pitney WR, Merskey C, O’Brien JR. Christmas Disease. BMJ 1952; 2: 1378. doi: http://dx.doi.org/10.1136/bmj.2.4799.1378
• 2. Rogaev EI, Grigorenko AP, Faskhutdinova G, Kittler EL, Moliaka YK. Genotype Analysis Identifies the Cause of the “Royal Disease”. Science 2009: 326; 817. doi: 10.1126/science.1180660.
• 3. Quick AJ, Hussey CV. Hemophilia B (PTC deficiency, or Christmas disease). Arch Intern Med 1959; 103: 762–75. doi:10.1001/archinte.1959.00270050084014.
• 4. Mannucci PM, Franchini M. Is haemophilia B less severe than haemophilia A? Haemophilia 2013; 19: 499-502. doi: 10.1111/hae.12133.
• 5. Reijnen MJ, Sladek FM, Bertina RM, Reitsma PH. Disruption of a binding site for hepatocyte nuclear factor 4 results in hemophilia B Leyden. Proc Natl Acad Sci USA. 1992; 89: 6300-3.
• 6. Nathwani AC, Tuddenham EG, Rangarajan S, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 2011; 365: 2357-65. doi: 10.1056/NEJMoa1108046.
• 7. Nathwani AC, Reiss UM, Tuddenham EG, Rosales C, Chowdary P, McIntosh J, et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med 2014; 371: 1994-2004. doi: 10.1056/NEJMoa1407309.
• 8. Collins PW, Young G, Knobe K, et al. Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial. Blood First Edition Paper, prepublished online September 26, 2014; DOI 10.1182/blood-2014-05-573055